Cardinal Health (CAH)
(Delayed Data from NYSE)
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 6:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.28 USD
+0.11 (0.10%)
Updated Sep 16, 2024 04:00 PM ET
After-Market: $113.27 -0.01 (-0.01%) 6:28 PM ET
3-Hold of 5 3
A Value A Growth A Momentum A VGM
Zacks News
Here is What to Know Beyond Why Cardinal Health, Inc. (CAH) is a Trending Stock
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
The Zacks Analyst Blog Highlights Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial
by Zacks Equity Research
Cardinal Health, The Coca-Cola, General Mills, The Clorox and Cincinnati Financial are part of the Zacks top Analyst Blog.
QuidelOrtho's (QDEL) Rapid Antigen Test Gets De Novo FDA Approval
by Zacks Equity Research
QuidelOrtho's (QDEL) receipt of the FDA's De Novo approval is expected to enable it to provide the test as an aid in the diagnosis of SARS-CoV-2 infections in symptomatic individuals.
5 Safe Stocks to Buy as SVB Collapse Shakes Wall Street
by Nalak Das
At this stage, it will be prudent to stay with safe stocks.Five such stocks are: CAH, CINF, CLX, KO and GIS.
After Plunging -10.82% in 4 Weeks, Here's Why the Trend Might Reverse for Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Cardinal Health (CAH) Stock Moves -0.14%: What You Should Know
by Zacks Equity Research
Cardinal Health (CAH) closed the most recent trading day at $71.19, moving -0.14% from the previous trading session.
Cardinal Health's (CAH) New Tie-Up to Boost Patient Outcomes
by Zacks Equity Research
Cardinal Health's (CAH) latest partnership is expected to improve patients' healthcare journey by offering a more integrated experience that connects all sites of care.
3 Reasons Growth Investors Will Love Cardinal (CAH)
by Zacks Equity Research
Cardinal (CAH) possesses solid growth attributes, which could help it handily outperform the market.
Here's Why You Should Add Stryker (SYK) Stock to Your Portfolio
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic arm-assisted surgery platform, Mako, and its broad product portfolio. However, pricing pressure weighs on it.
Are Investors Undervaluing Cardinal Health (CAH) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
CVS Health's (CVS) New Acquisitions Aid, Cost Woes Linger
by Zacks Equity Research
CVS Health (CVS) launches functionality that gives patients more choices and convenience in filling prescriptions.
Is Trending Stock Cardinal Health, Inc. (CAH) a Buy Now?
by Zacks Equity Research
Cardinal (CAH) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
IDEXX (IDXX) Global Sales, Instrument Placement Robust
by Zacks Equity Research
IDEXX (IDXX) continues to demonstrate solid growth globally, primarily aided by a gain in CAG and Water businesses.
Teleflex (TFX) Q4 Earnings Top Estimates, Operating Margin Down
by Zacks Equity Research
Teleflex (TFX) revenues in Asia rise backed by strong contributions from growth in all geographies.
Chemed (CHE) Q4 Earnings Beat Estimates, Margins Contract
by Zacks Equity Research
Chemed (CHE) reports impressive sales growth in the Roto-Rooter subsidiary in the fourth quarter of 2022.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Margins Down
by Zacks Equity Research
Inflationary costs, supply chain disruptions, volatility in foreign exchange rates and the persistent COVID-led impact hurt NuVasive's (NUVA) Q4 revenues.
Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips
by Zacks Equity Research
Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.
Integra Lifesciences (IART) Q4 Earnings Top, Revenues Drop Y/Y
by Zacks Equity Research
Integra LifeSciences (IART) delivers strong earnings growth in the fourth quarter amid challenging macro environment issues.
Charles River (CRL) Q4 Earnings Top Estimates, Margins Dip
by Zacks Equity Research
Strength across the DSA and Research Models and Services RMS business segments drove Charles River's (CRL) Q4 revenues.
Exact Sciences (EXAS) Q4 Earnings Top Estimates, Margin Falls
by Zacks Equity Research
Robust revenues from the Screening and Precision Oncology segments contributed to the Exact Sciences (EXAS) Q4 top line.
Walgreens' (WBA) New Partnerships Aid, Margin Pressure Ails
by Zacks Equity Research
Walgreens Boots (WBA) raises its U.S. Healthcare target, including fiscal 2025 sales goal.
Globus Medical (GMED) Q4 Earnings Beat, Operating Margin Rises
by Zacks Equity Research
Globus Medical (GMED) reports strong fourth-quarter sales growth amid currency headwinds and lingering COVID-19 impacts.
Medtronic (MDT) Q3 Earnings Beat Estimates, Margins Down
by Zacks Equity Research
Medtronic's (MDT) CGM business banks on strong sales of the MiniMed 780G system and the associated increase in CGM attachment rates on the strength of the Guardian 4 sensor in Q3.
Quest Diagnostics (DGX) Base Business Growth Robust, Volume Up
by Zacks Equity Research
Quest Diagnostics (DGX) starts to benefit from incentives related to these value-based contracts, which help demonstrate the value of these strategic relationships.
Medtronic (MDT) Receives CE Mark Approval For Aurora System
by Zacks Equity Research
Medtronic (MDT) Aurora EV-ICD system indicated for patients at risk of life-threatening arrhythmias.